CN103565784A - Weight-reducing preparation - Google Patents
Weight-reducing preparation Download PDFInfo
- Publication number
- CN103565784A CN103565784A CN201310534754.0A CN201310534754A CN103565784A CN 103565784 A CN103565784 A CN 103565784A CN 201310534754 A CN201310534754 A CN 201310534754A CN 103565784 A CN103565784 A CN 103565784A
- Authority
- CN
- China
- Prior art keywords
- weight
- clenbuterol
- reducing
- application
- treating obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a weight-reducing preparation, relates to novel application of clenbuterol hydrochloride series medicines in the field of pharmacy, and aims to solve the technical problem of weight reducing of an obese patient by means of clenbuterol hydrochloride series medicines. The weight-reducing preparation is characteristics that the weight-reducing function of clenbuterol hydrochloride is sufficiently utilized. The weight-reducing preparation is mainly used for inhibiting, reducing adipopexis, reducing weight, treating obese diseases, and preventing diabetes mellitus, heart disease, cardiovascular and cerebrovascular and other severe internal medicine diseases caused by adipopexis and obesity.
Description
Technical field
The invention of this purposes relates to hydrochloric acid Ke Lunluo medicine series in the new purposes of pharmaceutical field.
Background technology
Clenobuterol hydrochloride; A kind of anti-asthmatic.This medicine is neither veterinary drug, neither feed additive, but adrenal gland's class nervous stimulant.Clenbuterol Hydrochloride; Clenbuterol; Clenbuterol hydrochloride; Clenbuterol; Clenbuterol hydrochioride; Ammonia Celenbuterol; 7-[2-methylpropane 2-iminomethyl] 4-amino 3,5-dichlorbenzyl alcohol hydrochlorate.
[0002] clenobuterol hydrochloride medicine is taken in after human or animal's human body, in metabolic process, can promote protein synthesis, accelerates fatty conversion and decomposition, suppresses, reduces lipopexia.
Clenobuterol hydrochloride skeleton symbol:
Molecular formula: C12-H18-Cl2-N2-O
Physicochemical property: the crystalline powder of white or off-white color, odorless, bitter in the mouth, 161 ℃ of fusing points, water-soluble, ethanol, is slightly soluble in acetone, is insoluble to ether.
Food and Drug Administration extensively and has repeatedly assessed its effectiveness and safety.A large amount of evidence clenobuterol hydrochloride additions at 18 grams/ton in the go on the market effect of first 90 pounds of market pig.In these trials, clenobuterol hydrochloride improves without fat lean meat 34%.Clenobuterol hydrochloride has reduced feed intake when improving the speed of growth, and the 10th ribbed back fat thickness reduces by 13.7%.
Hydrochloric acid Ke Lunluo medicine series Clenbuterol; The two isoprophenamines of amine; Clenbuterol; Clenbuterol; Salt amine Celenbuterol, clenbuterol hydrochioride, clenbuterol hydrochloride, Celenbuterol, is potent selectivity beta 2 receptor agonist, its lax bronchial smooth muscle effect is strong and lasting, but less on cardiovascular system impact.Its bronchiectatic activity is about 100 times of albuterol, therefore dosage is minimum.For preventing and treating the bronchospasm due to the respiratory system diseases such as bronchial asthma and asthma type chronic bronchitis, emphysema.
At present known, for suppressing, reduce lipopexia, fat-reducing, treatment of obesity disease, and in the medicine catalogue of other serious symptom internal disease such as the diabetes that cause thus of prevention, heart disease, cardiovascular and cerebrovascular vessel, also clenobuterol hydrochloride medicine series preparation is not listed in wherein.
Summary of the invention
The inhibition that this purposes invention possesses by clenobuterol hydrochloride medicine series, reduces lipopexia, weight losing function, treatment of obesity disease, and other serious symptom internal disease such as the diabetes that cause thus of prevention, heart disease, cardiovascular and cerebrovascular vessel.
Technical scheme
The acid pharmacological action of the logical invention persalt Clenbuterol medicine series of this purposes, make human body can promote protein synthesis in metabolic process, accelerate fatty conversion and decomposition, suppress, reduce lipopexia, thereby reach fat-reducing treatment of obesity disease, the expected effect of other serious symptom internal diseases such as the diabetes that prevention causes thus, heart disease, cardiovascular and cerebrovascular vessel.
Know-why
Clenobuterol hydrochloride medicine series has significant nutrition " redistribution effects ", promotes that animal body is proteins deposited, promotes steatolysis to suppress lipidosis, can significantly improve weight and the medicine conversion ratio of trunk,
Clenobuterol hydrochloride medicine series possesses inhibition strongly, reduces lipopectic function, once and fat contact Clenbuterol will constantly cause and clear up in a large number, and loss gradually.This just makes the application of clenobuterol hydrochloride medicine series in the medicine of other serious symptom internal diseases such as the diabetes of preparing treatment of obesity disease and prevent to cause thus, heart disease, cardiovascular and cerebrovascular vessel, will bear indispensable effect.
Beneficial effect
(1), this purposes invents known salts Clenbuterol medicine series, excavated new medical application, opened up a new application.
(2), this purposes invention puzzlement of excessively accumulating other serious symptom internal diseases such as bring to obesity patient handicapped, mental pressure and the diabetes that cause thus, heart disease, cardiovascular and cerebrovascular vessel for dispelling fat torments, and opened up new medication source.
(3), this purposes invention clenobuterol hydrochloride medicine series is through clinical verification for many years, relatively low because of its ratio of contained dosage in medicine, toxic and side effects is in controlled range, pharmacological action is strong, is indicating well prospect in medicine.
(4), the clenobuterol hydrochloride medicine series of this purposes invention, products material source is abundant, inexpensive, preparation technology is simple, easy to use.
(5), strong, the efficacy of a drug of this purposes invention clenobuterol hydrochloride medicine series property of medicine is lasting, be difficult for recurrence, curative effect is obvious, can receive fat-reducing effect significantly in several weeks to the several months.
Specific embodiments
(1), strictly defer to the relevant package inserts such as Clenbuterol Hydrochloride, clenbuterol, clenbuterol hydrochloride, Clenbuterol, clenbuterol hydrochioride, ammonia Celenbuterol or take in accordance with doctor's advice; It within every 3 months, is a course for the treatment of; Forbid mixing with other external used medicine or the use that superposes;
(2), untoward reaction: clenobuterol hydrochloride medicine series is mainly distributed in liver after entering in human body.In muscle, content is much lower compared with liver.After people takes in, retention time is longer in vivo, its untoward reaction mainly contains: can cause that heart rate accelerates, more easily there is cardiac response in original ARR case particularly, visible ventricular premature beat, ST section and T wave amplitude force down, also can send muscular tremor, initiation extremity, neck surface skeletal muscle tremble, and especially the case of sympathetic hyperfunction more easily occurs.In addition, also can cause that metabolism disorder, blood potassium reduce.
(3), the performance of the poisoning symptom of clenobuterol hydrochloride medicine series is more special, be mainly have palpitation, muscular tremor, headache and face's flushing etc.In general do not have large problem, but the patient of the diseases such as arrhythmia, hypertension, glaucoma, diabetes, hyperthyroidism is had to larger harm.
Claims (1)
1. a slimming agents.The inhibition that the present invention possesses by clenobuterol hydrochloride medicine series, minimizing lipopexia, weight losing function, the application in other serious symptom internal disease medicaments such as the diabetes that treatment of obesity disease and prevention cause thus, heart disease, cardiovascular and cerebrovascular vessel.Comprise:
(1), the application of Clenbuterol Hydrochloride in preparing medicament for treating obesity.
(2), the application of clenbuterol in preparing medicament for treating obesity.
(3), the application of clenbuterol hydrochloride in preparing medicament for treating obesity.
(4), the application of Clenbuterol in preparing medicament for treating obesity.
(5), the application of clenbuterol hydrochioride in preparing medicament for treating obesity.
(6), the application of ammonia Celenbuterol in preparing medicament for treating obesity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310534754.0A CN103565784A (en) | 2013-11-04 | 2013-11-04 | Weight-reducing preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310534754.0A CN103565784A (en) | 2013-11-04 | 2013-11-04 | Weight-reducing preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103565784A true CN103565784A (en) | 2014-02-12 |
Family
ID=50039067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310534754.0A Pending CN103565784A (en) | 2013-11-04 | 2013-11-04 | Weight-reducing preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103565784A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018011588A1 (en) * | 2016-07-13 | 2018-01-18 | Atrogi Ab | Combinations of adrenergic receptor agonists for the treatment of type 2 diabetes |
| US10288602B2 (en) | 2013-01-08 | 2019-05-14 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatement |
| US11357757B2 (en) | 2017-09-13 | 2022-06-14 | Atrogi Ab | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia |
| US11427539B2 (en) | 2017-09-13 | 2022-08-30 | Atrogi Ab | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia |
| US11648216B2 (en) | 2017-09-13 | 2023-05-16 | Atrogi Ab | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia |
| US11793774B2 (en) | 2017-09-13 | 2023-10-24 | Atrogi Ab | Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia |
-
2013
- 2013-11-04 CN CN201310534754.0A patent/CN103565784A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10288602B2 (en) | 2013-01-08 | 2019-05-14 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatement |
| WO2018011588A1 (en) * | 2016-07-13 | 2018-01-18 | Atrogi Ab | Combinations of adrenergic receptor agonists for the treatment of type 2 diabetes |
| US11357757B2 (en) | 2017-09-13 | 2022-06-14 | Atrogi Ab | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia |
| US11427539B2 (en) | 2017-09-13 | 2022-08-30 | Atrogi Ab | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia |
| US11648216B2 (en) | 2017-09-13 | 2023-05-16 | Atrogi Ab | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia |
| US11793774B2 (en) | 2017-09-13 | 2023-10-24 | Atrogi Ab | Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia |
| US12036210B2 (en) | 2017-09-13 | 2024-07-16 | Atrogi Ab | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103565784A (en) | Weight-reducing preparation | |
| US20110311478A1 (en) | Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium | |
| CN101460159A (en) | Fatigue-reducing agent | |
| CN102885856B (en) | Production method for producing medicine for treating hepatitis B by periplaneta americana extract | |
| CN110840895A (en) | Method for promoting gastrointestinal system motility using vitamin B composition | |
| FI3356386T3 (en) | Method of treating melanocortin-4 receptor pathway-associated disorders | |
| CN109476701A (en) | Comprising ring His-Pro as effective component for protecting the composition of cell | |
| WO2006042479A9 (en) | Pharmaceutical composition and non dependence coffee comprising edible carboxylic acid and/or its acid salt and coffeine | |
| WO2014180239A1 (en) | Pharmaceutical composition for treating severe altitude sickness | |
| WO2004019928A1 (en) | Therapeutic agent for hepatic disease | |
| CN103989677A (en) | Use of demethyleneberberine in preparation of blood sugar-reduction drug | |
| CN108771246B (en) | Composition for improving immunity and restoring physiological function of patients after operation or chemotherapy | |
| US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN116173177A (en) | Pharmaceutical composition for continuously improving male sexual function and preparation method thereof | |
| TWI224506B (en) | Pharmaceutical composition | |
| CN102743419A (en) | Preparation method and application of liquidambar formosana hance fruit total tannins extract | |
| CN103550251B (en) | Hydrocortisone sodium succinate compound pharmaceutical composition | |
| WO2020063262A1 (en) | Application of 3'-deoxyinosine in preparation of drug, food or health product for multiple disease | |
| JP2011178702A (en) | Agent for improving sleep | |
| CN109464441B (en) | Application of 3-acetamido coumarin in preparing medicine for treating or preventing hyperuricemia and kidney injury | |
| KR100950255B1 (en) | Composition having congnition enhancing activity comprising Betula Platy Phylla sap | |
| CN101596203B (en) | Application of syringin in preparing drugs for treating cardiovascular and cerebrovascular diseases | |
| TW536400B (en) | Pharmaceutical composition for the treatment of immunodeficiency disease which cause by HIV infection | |
| WO2020168760A1 (en) | Use of albiflorin in preparation of drugs for rapidly treating depression | |
| CN1481796A (en) | Medication for adiposity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Jixi City, Heilongjiang province Tiedong 158100 Jiguan district committee 10 group Applicant after: Kuang Zhongping Address before: 300384 Tianjin city Nankai District Huayuan District in No. 9 Building 3 1005 Li Applicant before: Kuang Zhongping |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140212 |